Correspondingly, the apoptotic cell percentage of ovarian cancer HO8910 cells treated with DDP/CD44-shRNA/MFH was (89.12 ± 0.83)%, much higher than any of the other groups [negative control group: (9.89 ± 0.91)%; DDP group: (21.33 ± 2.22)%; DDP/CD44-shRNA group: (44.59 ± 3.93)%; MFH group: (54.13 ± 3.14)%; CD44-shRNA/MFH group: (78.88 ± 0.07)%; DDP/MFH group: (81.87 ± 1.93)%, p<0.05] (Figure 5B). Here, CD44 is linked to ovarian carcinoma.